CN117919274A - Hemodialysis concentrate - Google Patents
Hemodialysis concentrate Download PDFInfo
- Publication number
- CN117919274A CN117919274A CN202410024290.7A CN202410024290A CN117919274A CN 117919274 A CN117919274 A CN 117919274A CN 202410024290 A CN202410024290 A CN 202410024290A CN 117919274 A CN117919274 A CN 117919274A
- Authority
- CN
- China
- Prior art keywords
- hemodialysis
- solution
- concentration
- supplement
- hemodialysis concentrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000001631 haemodialysis Methods 0.000 title claims abstract description 51
- 230000000322 hemodialysis Effects 0.000 title claims abstract description 51
- 239000012141 concentrate Substances 0.000 title claims abstract description 42
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims abstract description 61
- 229910052742 iron Inorganic materials 0.000 claims abstract description 41
- FINHMKGKINIASC-UHFFFAOYSA-N Tetramethylpyrazine Chemical compound CC1=NC(C)=C(C)N=C1C FINHMKGKINIASC-UHFFFAOYSA-N 0.000 claims abstract description 40
- 239000013589 supplement Substances 0.000 claims abstract description 39
- 238000000502 dialysis Methods 0.000 claims abstract description 30
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 21
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims abstract description 20
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims abstract description 20
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims abstract description 20
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 claims abstract description 19
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 17
- 239000008103 glucose Substances 0.000 claims abstract description 17
- 239000012530 fluid Substances 0.000 claims abstract description 14
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims abstract description 10
- 239000001110 calcium chloride Substances 0.000 claims abstract description 10
- 229910001628 calcium chloride Inorganic materials 0.000 claims abstract description 10
- 229910001629 magnesium chloride Inorganic materials 0.000 claims abstract description 10
- 239000001103 potassium chloride Substances 0.000 claims abstract description 10
- 235000011164 potassium chloride Nutrition 0.000 claims abstract description 10
- 235000017557 sodium bicarbonate Nutrition 0.000 claims abstract description 10
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims abstract description 10
- 239000011780 sodium chloride Substances 0.000 claims abstract description 10
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims abstract description 9
- 239000003002 pH adjusting agent Substances 0.000 claims abstract description 5
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
- PMVSDNDAUGGCCE-TYYBGVCCSA-L Ferrous fumarate Chemical compound [Fe+2].[O-]C(=O)\C=C\C([O-])=O PMVSDNDAUGGCCE-TYYBGVCCSA-L 0.000 claims description 10
- 239000011773 ferrous fumarate Substances 0.000 claims description 10
- 235000002332 ferrous fumarate Nutrition 0.000 claims description 10
- 229960000225 ferrous fumarate Drugs 0.000 claims description 10
- NPFOYSMITVOQOS-UHFFFAOYSA-K iron(III) citrate Chemical compound [Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NPFOYSMITVOQOS-UHFFFAOYSA-K 0.000 claims description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 229960002413 ferric citrate Drugs 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 229960000583 acetic acid Drugs 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 239000012362 glacial acetic acid Substances 0.000 claims description 4
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 3
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 3
- 235000001014 amino acid Nutrition 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 235000015165 citric acid Nutrition 0.000 claims description 3
- 239000004310 lactic acid Substances 0.000 claims description 3
- 235000014655 lactic acid Nutrition 0.000 claims description 3
- 239000001630 malic acid Substances 0.000 claims description 3
- 235000011090 malic acid Nutrition 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 239000000047 product Substances 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- 239000011788 ferric saccharate Substances 0.000 claims 1
- 235000008824 ferric saccharate Nutrition 0.000 claims 1
- XRDYWGSODBNAIE-BQGRAUOOSA-K iron(3+);(2r,3s,4s,5s)-2,3,4,5,6-pentahydroxy-6-oxohexanoate Chemical compound [Fe+3].OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O XRDYWGSODBNAIE-BQGRAUOOSA-K 0.000 claims 1
- -1 iron ions Chemical class 0.000 abstract description 21
- 238000011282 treatment Methods 0.000 abstract description 15
- 239000008280 blood Substances 0.000 abstract description 12
- 210000004369 blood Anatomy 0.000 abstract description 12
- 208000007502 anemia Diseases 0.000 abstract description 8
- 230000007774 longterm Effects 0.000 abstract description 7
- 208000024891 symptom Diseases 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 4
- 235000016709 nutrition Nutrition 0.000 abstract description 4
- 230000035764 nutrition Effects 0.000 abstract description 4
- 206010070863 Toxicity to various agents Diseases 0.000 abstract description 3
- 238000009423 ventilation Methods 0.000 abstract description 3
- 208000009304 Acute Kidney Injury Diseases 0.000 abstract description 2
- 208000033626 Renal failure acute Diseases 0.000 abstract description 2
- 230000001154 acute effect Effects 0.000 abstract description 2
- 201000011040 acute kidney failure Diseases 0.000 abstract description 2
- 208000012998 acute renal failure Diseases 0.000 abstract description 2
- 208000020832 chronic kidney disease Diseases 0.000 abstract description 2
- 208000022831 chronic renal failure syndrome Diseases 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 27
- 239000000126 substance Substances 0.000 description 7
- FWZTTZUKDVJDCM-CEJAUHOTSA-M disodium;(2r,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol;iron(3+);oxygen(2-);hydroxide;trihydrate Chemical compound O.O.O.[OH-].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[Na+].[Na+].[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Fe+3].O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 FWZTTZUKDVJDCM-CEJAUHOTSA-M 0.000 description 6
- 229940032961 iron sucrose Drugs 0.000 description 6
- 230000004089 microcirculation Effects 0.000 description 6
- 102000001554 Hemoglobins Human genes 0.000 description 5
- 108010054147 Hemoglobins Proteins 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 4
- 210000002565 arteriole Anatomy 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000003727 cerebral blood flow Effects 0.000 description 3
- 201000001421 hyperglycemia Diseases 0.000 description 3
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 3
- 208000002720 Malnutrition Diseases 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 235000000824 malnutrition Nutrition 0.000 description 2
- 230000001071 malnutrition Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 208000015380 nutritional deficiency disease Diseases 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 208000037157 Azotemia Diseases 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 150000003627 tricarboxylic acid derivatives Chemical class 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a hemodialysis concentrate, which relates to the technical field of hemodialysis and comprises the following components: fluid a, fluid B and supplements; the solution A comprises: sodium chloride, potassium chloride, calcium chloride, magnesium chloride, and pH adjuster; the solution B comprises: sodium bicarbonate; the supplement comprises iron, ligustrazine, ketoglutaric acid, and glucose. The hemodialysis concentrate provided by the invention can be suitable for hemodialysis treatment of patients suffering from acute and chronic renal failure and drug poisoning, and has an excellent market prospect. The iron ions are supplemented into the hemodialysis concentrate by adding the components rich in the iron ions, so that the iron ions enter a human body to relieve anemia symptoms caused by blood loss caused by long-term ventilation treatment, and meanwhile, the hemodialysis concentrate can supplement nutrition, required elements, energy and the like for patients subjected to long-term dialysis, so that the effect of dialysis treatment is improved, and discomfort of the patients is relieved.
Description
Technical Field
The invention relates to the technical field of hemodialysis, in particular to a hemodialysis concentrate.
Background
Hemodialysis is a treatment form in which blood in a patient is led out of the body and then purified, pathogenic substances in the blood are removed to achieve the aim of purification, and then the blood is returned, and is commonly used for treating diseases such as aging, uremia, nephropathy, hyperlipidemia, drug poisoning and the like, and is a long-term treatment means for certain diseases.
The existing hemodialysis concentrate can filter and purify harmful substances, has certain gain, is difficult to avoid blood loss in the long-term hemodialysis process, and can cause problems once the transfusion quantity of blood is reduced, for example, when beneficial substances such as iron ions, nutrient substances and the like contained in the blood are reduced, the corresponding patients can suffer from anemia, malnutrition and other complications after multiple times of dialysis, and the pain of the patients is increased.
Disclosure of Invention
The present invention aims to solve at least one of the technical problems of the prior art and to provide a hemodialysis concentrate.
The technical scheme of the invention is as follows:
a hemodialysis concentrate comprising the following components: fluid a, fluid B and supplements;
The solution A comprises: sodium chloride, potassium chloride, calcium chloride, magnesium chloride, and pH adjuster;
the solution B comprises: sodium bicarbonate;
the supplement comprises iron, ligustrazine, ketoglutaric acid, and glucose.
Preferably, in the solution A, the concentration of sodium chloride is 210.70g/1000ml,
The concentration of the potassium chloride is 5.22g/1000ml;
the concentration of the calcium chloride is 7.72g/1000ml;
The concentration of magnesium chloride is 3.56g/1000ml;
The concentration of the pH regulator was 8.41g/1000ml.
Further, the pH regulator is one or more of glacial acetic acid, citric acid, lactic acid, malic acid and amino acid.
Preferably, in the solution B, the concentration of sodium bicarbonate is 84.00g/1000ml.
Preferably, in the supplement, the iron agent comprises one or more of ferrous fumarate, ferric sucrose and ferric citrate, and the total content of iron in the supplement is 0.127-0.232g/1000ml.
Preferably, the content of ligustrazine in the supplement is 0.113-0.235g/1000ml.
Preferably, the content of ketoglutaric acid in the supplement is 0.0009-0.0042g/1000ml.
Preferably, the glucose content in the supplement is 0.0021-0.0113g/1000ml.
The invention discloses a preparation method of hemodialysis concentrate, which comprises the steps of weighing the contents of the components of solution A, solution B and replenisher respectively, adding dialysis water respectively, fully dissolving to reach acceptable concentration, and uniformly mixing.
The beneficial effects of the invention are as follows:
(1) The hemodialysis concentrate provided by the invention can be suitable for hemodialysis treatment of patients suffering from acute and chronic renal failure and drug poisoning, and has an excellent market prospect.
(2) According to the hemodialysis concentrate, the iron ions are supplemented in the hemodialysis concentrate by adding the component rich in the iron ions, so that the iron ions enter a human body to relieve the anemia symptoms caused by blood loss due to long-term ventilation treatment.
(3) The hemodialysis concentrate is prepared according to a certain formula by using the supplement, and glucose and ketoglutaric acid are added at the same time, so that the hemodialysis concentrate can supplement nutrition, required elements, energy and the like to patients subjected to long-term dialysis, and the effect of dialysis treatment is improved, and discomfort of the patients is relieved.
(4) The hemodialysis concentrate of the invention can effectively improve hyperglycemia of patients, increase blood flow and improve renal microcirculation by adding the ligustrazine, and the ligustrazine can inhibit platelet aggregation to a certain extent so as to expand arterioles, thereby playing a role in improving microcirculation and cerebral blood flow.
Detailed Description
A hemodialysis concentrate comprising the following components: fluid a, fluid B and supplements;
The solution A comprises: sodium chloride, potassium chloride, calcium chloride, magnesium chloride, and pH adjuster;
the solution B comprises: sodium bicarbonate;
the supplement comprises iron, ligustrazine, ketoglutaric acid, and glucose.
Specifically, in the solution A, the concentration of sodium chloride is 210.70g/1000ml,
The concentration of the potassium chloride is 5.22g/1000ml;
the concentration of the calcium chloride is 7.72g/1000ml;
The concentration of magnesium chloride is 3.56g/1000ml;
pH regulator 8.41g/1000ml.
Further, the pH regulator is one or more of glacial acetic acid, citric acid, lactic acid, malic acid and amino acid.
Preferably, in the solution B, the concentration of sodium bicarbonate is 84.00g/1000ml.
Preferably, in the supplement, the iron agent comprises one or more of ferrous fumarate, ferric sucrose and ferric citrate, and the total content of iron in the supplement is 0.127-0.232g/1000ml. The concrete composition comprises the following components in percentage by weight:
ferrous fumarate is 0.392-0.589g/1000ml;
Iron sucrose is 0.303-0.854g/1000ml;
ferric citrate is 0.536-0.801g/1000ml;
Preferably, the content of ligustrazine in the supplement is 0.113-0.235g/1000ml.
Preferably, the content of ketoglutaric acid in the supplement is 0.0009-0.0042g/1000ml.
Preferably, the glucose content in the supplement is 0.0021-0.0113g/1000ml.
Ferrous fumarate is one of the pharmaceutical ingredients for treating anemia, and can improve the anti-stress capability and the disease resistance capability, so that the ferrous fumarate has good compatibility with various nutrient substances and antibiotics; iron sucrose and iron citrate are commonly used iron supplementing components, wherein iron citrate is commonly used as food iron fortifier and nutritional supplement in actual use, so that one or more of ferrous fumarate, iron sucrose and iron citrate can be used for supplementing iron for patients after being combined, and anemia is a common complication of hemodialysis in the process of dialysis treatment, so that the anemia is one of the key points of dialysis treatment, namely iron is absent in the body, and 1g of iron ions can be lost in dialysis patients each year due to the fact that the patients have to have certain blood loss in dialysis, and the invention can slowly supplement iron lost in the process of dialysis by adding 0.127-0.232g/1000ml of iron into hemodialysis concentrate, and can be combined with transferrin and transported into bone marrow to form hematopoiesis after entering blood of patients in the process of dialysis, so that the prescription can help weaken anemia of dialysis patients.
The ligustrazine can effectively improve hyperglycemia of patients, increase blood flow and improve renal microcirculation, inhibit platelet aggregation to a certain extent so as to expand arterioles, and has the effects of improving microcirculation and cerebral blood flow, and the ligustrazine is added into the solution A due to acidity.
The ketoglutaric acid, in particular a-ketoglutaric acid, is a tricarboxylic acid, and the addition of a-ketoglutaric acid to hemodialysis concentrate provides an additional source of energy which helps to correct post-dialysis debilitating symptoms and thus improve the nutritional status of the patient.
Because the patient loses a large amount of nutrient substances during long-time dialysis treatment, glucose is further added into the hemodialysis concentrate, so that the nutrient substances can be slowly infused to supplement the lost amount during the dialysis process during the hemodialysis, thereby ensuring the nutrition requirements of the dialysis patient.
The method for preparing hemodialysis concentrate comprises respectively weighing the solution A, the solution B and the components of the supplement, respectively adding dialysis water, fully dissolving to reach acceptable concentration, and uniformly mixing.
More specifically, the hemodialysis concentrate may be specifically a dry powder or concentrate.
Embodiments of the present invention are described in detail below. The following examples are illustrative only and are not to be construed as limiting the invention. The examples are not to be construed as limiting the specific techniques or conditions described in the literature in this field or as per the specifications of the product. The reagents or apparatus used were conventional products commercially available without the manufacturer's attention.
Example 1
A hemodialysis concentrate comprising the following components: fluid a, fluid B and supplements;
in the solution A, the concentration of sodium chloride is 210.70g/1000ml,
The concentration of the potassium chloride is 5.22g/1000ml;
the concentration of the calcium chloride is 7.72g/1000ml;
The concentration of magnesium chloride is 3.56g/1000ml;
the concentration of the pH regulator (glacial acetic acid) is 8.41g/1000ml;
in the solution B, the concentration of sodium bicarbonate is 84.00g/1000ml;
the supplement comprises iron, ligustrazine, ketoglutaric acid, and glucose.
Ferrous fumarate at 0.392g/1000ml;
iron sucrose is 0.0.854g/1000ml;
Ferric citrate is 0.536g/1000ml;
the content of ligustrazine is 0.113g/1000ml;
the content of ketoglutaric acid is 0.0009g/1000ml;
the glucose content is 0.0021g/1000ml;
the ratio of solution A, solution B and water per liter of hemodialysis concentrate was 1:1.23:32.77.
Example 2
A hemodialysis concentrate comprising the following components: fluid a, fluid B and supplements;
in the solution A, the concentration of sodium chloride is 210.70g/1000ml,
The concentration of the potassium chloride is 5.22g/1000ml;
the concentration of the calcium chloride is 7.72g/1000ml;
The concentration of magnesium chloride is 3.56g/1000ml;
the concentration of the pH regulator (citric acid) is 8.41g/1000ml;
in the solution B, the concentration of sodium bicarbonate is 84.00g/1000ml;
the supplement comprises iron, ligustrazine, ketoglutaric acid, and glucose.
Ferrous fumarate at 0.512g/1000ml;
Iron sucrose is 0.516g/1000ml;
ferric citrate is 0.601g/1000ml;
The content of ligustrazine is 0.152g/1000ml;
the content of ketoglutaric acid is 0.0021g/1000ml;
Glucose content was 0.0089g/1000ml;
the ratio of solution A, solution B and water per liter of hemodialysis concentrate was 1:1.23:32.77.
Example 3
A hemodialysis concentrate comprising the following components: fluid a, fluid B and supplements; in the solution A, the concentration of sodium chloride is 210.70g/1000ml,
The concentration of the potassium chloride is 5.22g/1000ml;
the concentration of the calcium chloride is 7.72g/1000ml;
The concentration of magnesium chloride is 3.56g/1000ml;
the concentration of the pH regulator (amino acid) was 8.41g/1000ml;
in the solution B, the concentration of sodium bicarbonate is 84.00g/1000ml;
the supplement comprises iron, ligustrazine, ketoglutaric acid, and glucose.
Ferrous fumarate is 0.589g/1000ml;
iron sucrose is 0.854g/1000ml;
the ferric citrate is 0.801g/1000ml;
The content of ligustrazine is 0.235g/1000ml;
The content of ketoglutaric acid is 0.0042g/1000ml;
Glucose content is 0.0113g/1000ml;
the ratio of solution A, solution B and water per liter of hemodialysis concentrate was 1:1.23:32.77.
Comparative example 1 (no supplement added)
The present example was modified on the basis of example 1 without supplements.
The test method comprises the following steps: the arterial ends of a 500mL disinfection bottle and a dialysis pipeline are tightly connected by a soft rubber tube, physiological saline (containing 5mmol/L of iron ions) is used for carrying out extracorporeal circulation hemodialysis instead of blood, the content of the added iron ions in the physiological saline is equal to that of the iron ions in human serum, the flow rate is 200mL/min, the flow rate of the dialyzate is 500mL/min, the ultrafiltration amounts are 0.3kg/h, the model of a dialyzer is Below LO15, and the dialyzate is designed according to the content of the iron ions in the physiological saline which is 1 times, 1.5 times and 2 times respectively and the content of the iron ions in the dialyzate which is not added. After dialysis for 4 hours, the rate of change of the iron ion content in the physiological saline and dialysate side before and after dialysis was detected by an automatic biochemical analyzer. The results are shown in Table 1.
Table 1 results of the tests of examples and comparative examples
| Sample preparation | Example 1 | Example 2 | Example 3 | Comparative example 1 |
| Rate of change of iron ions | 0.11％ | 0.13％ | 0.12％ | Detection of iron ions |
| Rate of change of ligustrazine | 0.08％ | 0.10％ | 0.09％ | - |
| Rate of change of ketoglutaric acid | 0.11％ | 0.15％ | 0.13％ | - |
| Rate of change of glucose | 0.05％ | 0.08％ | 0.07％ | - |
The concentrates of example 1 and comparative example above were simultaneously subjected to dialysis treatment on dialysis patients.
Treatment group (example 1): of 30 dialysis patients, 18 men and 12 women had an average age of 45.6 years (20 to 70 years), and the average value of pre-treatment hemoglobin (Hb) was 83.5g/L;
general group (comparative example 1): of 30 dialysis patients, 17 men and 13 women had an average age of 42.7 years (20 to 70 years), and the average value of pre-treatment hemoglobin (Hb) was 83.2g/L;
the hemoglobin (Hb) index before and after hemodialysis was observed for both groups of dialysis patients, and the results are shown in table 2.
TABLE 2 hemoglobin (Hb) index before and after hemodialysis for two groups of dialysis patients
| Group of | Mean value of hemoglobin (Hb, g/L) | Other symptoms of |
| Treatment group | 115.8 | Good quality |
| Common group | 81.3 | Part of the total nutrient solution has the symptoms of hypoglycemia and malnutrition |
It can be seen from tables 1 and 2 that the iron ions in the examples of table 1 are not greatly changed, but the iron ions are detected in the dialysate without the iron additive, and most likely the normal saline water is lost into the dialysate, so that the iron ions are supplemented in the hemodialysis concentrate by adding the component rich in the iron ions, and the anemia symptoms caused by blood loss due to long-term ventilation treatment are relieved after the iron ions enter the human body. Meanwhile, the use of the supplement is found to be carried out according to a certain formula, and glucose and ketoglutaric acid are added at the same time, so that the hemodialysis concentrate can supplement nutrition, required elements, energy and the like for patients subjected to long-term dialysis, thereby improving the effect of dialysis treatment and relieving discomfort of the patients; furthermore, by adding the ligustrazine, the hyperglycemia condition of a patient can be effectively improved, the blood flow is increased, the renal microcirculation is improved, and the ligustrazine can inhibit platelet aggregation to a certain extent so as to expand arterioles, thereby playing a role in improving microcirculation and cerebral blood flow.
The foregoing examples have shown only the preferred embodiments of the invention, which are described in more detail and are not to be construed as limiting the scope of the invention. It should be pointed out that various other corresponding changes and modifications can be made by those skilled in the art in light of the above description of the technical solution and the idea, and all such changes and modifications are intended to be within the scope of the invention as defined in the appended claims.
Claims (9)
1. A hemodialysis concentrate comprising the following components: fluid a, fluid B and supplements;
The solution A comprises: sodium chloride, potassium chloride, calcium chloride, magnesium chloride, and pH adjuster;
the solution B comprises: sodium bicarbonate;
the supplement comprises iron, ligustrazine, ketoglutaric acid, and glucose.
2. A hemodialysis concentrate according to claim 1, wherein the concentration of sodium chloride in the solution A is 210.70g/1000ml,
The concentration of the potassium chloride is 5.22g/1000ml;
the concentration of the calcium chloride is 7.72g/1000ml;
The concentration of magnesium chloride is 3.56g/1000ml;
The concentration of the pH regulator was 8.41g/1000ml.
3. The hemodialysis concentrate of claim 1, wherein the pH adjuster in the solution B is one or more of glacial acetic acid, citric acid, lactic acid, malic acid, and amino acids.
4. A hemodialysis concentrate according to claim 1, wherein the concentration of sodium bicarbonate in the solution B is 84.00g/1000ml.
5. A hemodialysis concentrate according to claim 1, wherein the iron agent in the supplement comprises one or more of ferrous fumarate, ferric saccharate, ferric citrate, and the total iron content in the supplement is 0.127-0.232g/1000ml.
6. The hemodialysis concentrate of claim 1, wherein the supplement contains ligustrazine in an amount of 0.113-0.235g/1000ml.
7. A hemodialysis concentrate according to claim 1, wherein the content of ketoglutaric acid in the supplement is 0.0009-0.0042g/1000ml.
8. A hemodialysis concentrate according to claim 1, wherein the glucose content of the supplement is 0.0021-0.0113g/1000ml.
9. A process for the preparation of a hemodialysis concentrate according to any one of claims 1-8, characterized in that
Respectively weighing the contents of the components of the solution A, the solution B and the replenisher, respectively adding dialysis water,
Fully dissolving to the qualified concentration, and then uniformly mixing to obtain the product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410024290.7A CN117919274A (en) | 2024-01-08 | 2024-01-08 | Hemodialysis concentrate |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410024290.7A CN117919274A (en) | 2024-01-08 | 2024-01-08 | Hemodialysis concentrate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117919274A true CN117919274A (en) | 2024-04-26 |
Family
ID=90756714
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410024290.7A Pending CN117919274A (en) | 2024-01-08 | 2024-01-08 | Hemodialysis concentrate |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117919274A (en) |
-
2024
- 2024-01-08 CN CN202410024290.7A patent/CN117919274A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bergström | Nutrition and mortality in hemodialysis. | |
| EP1753437B1 (en) | Bicarbonate-based peritoneal dialysis solutions | |
| US8216172B2 (en) | Method of performing hemofiltration | |
| US6743191B1 (en) | Substitution infusion fluid and citrate anticoagulation | |
| KR102057555B1 (en) | Carboxylic Acid Mixtures to Treat Patients with Renal Failure | |
| Bellomo et al. | Prolonged intermittent renal replacement therapy in the intensive care unit | |
| JP2007500126A (en) | Dialysis solution with reduced levels of glucose breakdown products | |
| Chua et al. | Amino acid balance with extended daily diafiltration in acute kidney injury | |
| WO2010112547A1 (en) | Dialysis precursor composition | |
| CN103816182A (en) | Hemofiltration replacement fluid and preparation method thereof | |
| JP2002531051A (en) | Methods and pharmaceutical compositions for iron delivery in hemodialysis and peritoneal dialysis patients | |
| FREEMAN et al. | Hemodialysis for chronic renal failure: I. Technical considerations | |
| CN117919274A (en) | Hemodialysis concentrate | |
| CN108420828B (en) | Hemodialysis concentrate for improving residual renal function | |
| JPH0253723A (en) | Dialytic aqueous solution for abdominal administration and rinse solution | |
| Kobayashi et al. | Nitrogen metabolism in patients on peritoneal dialysis | |
| CN110063965A (en) | A kind of haemodialysis concentrate | |
| CN115811988A (en) | Blood purification molecule concentrate and preparation method and application thereof | |
| Davenport | Replacement and dialysate fluids for patients with acute renal failure treated by continuous veno-venous haemofiltration and/or haemodiafiltration | |
| Kindgen-Milles et al. | Treatment of metabolic alkalosis during continuous renal replacement therapy with regional citrate anticoagulation | |
| CN107854426A (en) | A kind of novel amino peritoneal dialysis solution | |
| CN116056715A (en) | Blood purification concentrate | |
| Evans et al. | Principles of renal replacement therapy in children | |
| WO2014095953A1 (en) | Dialysis composition | |
| Davenport et al. | Amino acid losses during haemofiltration |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |